Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2018 3
2019 1
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies.
Nikolic K, Mavridis L, Djikic T, Vucicevic J, Agbaba D, Yelekci K, Mitchell JB. Nikolic K, et al. Among authors: djikic t. Front Neurosci. 2016 Jun 10;10:265. doi: 10.3389/fnins.2016.00265. eCollection 2016. Front Neurosci. 2016. PMID: 27375423 Free PMC article. Review.
Synthesis, Molecular Docking and Anticancer Activity of Diflunisal Derivatives as Cyclooxygenase Enzyme Inhibitors.
Coşkun GP, Djikic T, Hayal TB, Türkel N, Yelekçi K, Şahin F, Küçükgüzel ŞG. Coşkun GP, et al. Among authors: djikic t. Molecules. 2018 Aug 6;23(8):1969. doi: 10.3390/molecules23081969. Molecules. 2018. PMID: 30082676 Free PMC article.
Synthesis, anticancer activity, and molecular modeling of etodolac-thioether derivatives as potent methionine aminopeptidase (type II) inhibitors.
Çoruh I, Çevik Ö, Yelekçi K, Djikic T, Küçükgüzel ŞG. Çoruh I, et al. Among authors: djikic t. Arch Pharm (Weinheim). 2018 Apr;351(3-4):e1700195. doi: 10.1002/ardp.201700195. Epub 2018 Mar 25. Arch Pharm (Weinheim). 2018. PMID: 29575045
Human dopamine transporter: the first implementation of a combined in silico/in vitro approach revealing the substrate and inhibitor specificities.
Djikic T, Martí Y, Spyrakis F, Lau T, Benedetti P, Davey G, Schloss P, Yelekci K. Djikic T, et al. J Biomol Struct Dyn. 2019 Feb;37(2):291-306. doi: 10.1080/07391102.2018.1426044. Epub 2018 Jan 26. J Biomol Struct Dyn. 2019. PMID: 29334320 Free article.
In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs.
Gagic Z, Ruzic D, Djokovic N, Djikic T, Nikolic K. Gagic Z, et al. Among authors: djikic t. Front Chem. 2020 Jan 8;7:873. doi: 10.3389/fchem.2019.00873. eCollection 2019. Front Chem. 2020. PMID: 31970149 Free PMC article. Review.
Synthesis and Screening of Human Monoamine Oxidase-A Inhibitor Effect of New 2-Pyrazoline and Hydrazone Derivatives.
Evranos-Aksöz B, Baysal İ, Yabanoğlu-Çiftçi S, Djikic T, Yelekçi K, Uçar G, Ertan R. Evranos-Aksöz B, et al. Among authors: djikic t. Arch Pharm (Weinheim). 2015 Oct;348(10):743-56. doi: 10.1002/ardp.201500212. Epub 2015 Aug 21. Arch Pharm (Weinheim). 2015. PMID: 26293971
Deciphering Imidazoline Off-targets by Fishing in the Class A of GPCR field.
Djikic T, Vucicevic J, Laurila J, Radi M, Veljkovic N, Xhaard H, Nikolic K. Djikic T, et al. Mol Inform. 2020 Jul;39(7):e1900165. doi: 10.1002/minf.201900165. Epub 2020 Mar 10. Mol Inform. 2020. PMID: 32078760
Bicyclic α-Iminophosphonates as High Affinity Imidazoline I2 Receptor Ligands for Alzheimer's Disease.
Abás S, Rodríguez-Arévalo S, Bagán A, Griñán-Ferré C, Vasilopoulou F, Brocos-Mosquera I, Muguruza C, Pérez B, Molins E, Luque FJ, Pérez-Lozano P, de Jonghe S, Daelemans D, Naesens L, Brea J, Loza MI, Hernández-Hernández E, García-Sevilla JA, García-Fuster MJ, Radan M, Djikic T, Nikolic K, Pallàs M, Callado LF, Escolano C. Abás S, et al. Among authors: djikic t. J Med Chem. 2020 Apr 9;63(7):3610-3633. doi: 10.1021/acs.jmedchem.9b02080. Epub 2020 Mar 19. J Med Chem. 2020. PMID: 32150414
In silico identification of novel 5-HT2A antagonists supported with ligand- and target-based drug design methodologies.
Radan M, Ruzic D, Antonijevic M, Djikic T, Nikolic K. Radan M, et al. Among authors: djikic t. J Biomol Struct Dyn. 2020 Mar 17:1-19. doi: 10.1080/07391102.2020.1738961. Online ahead of print. J Biomol Struct Dyn. 2020. PMID: 32141385
Feedback